Predictors of glycaemic control in patients with Type 1 diabetes commencing continuous subcutaneous insulin infusion therapy
Article first published online: 15 DEC 2009
© 2010 The Authors. Journal compilation © 2010 Diabetes UK
Volume 27, Issue 3, pages 339–347, March 2010
How to Cite
Shalitin, S., Gil, M., Nimri, R., De Vries, L., Gavan, M. Y. and Phillip, M. (2010), Predictors of glycaemic control in patients with Type 1 diabetes commencing continuous subcutaneous insulin infusion therapy. Diabetic Medicine, 27: 339–347. doi: 10.1111/j.1464-5491.2009.02925.x
- Issue published online: 1 MAR 2010
- Article first published online: 15 DEC 2009
- Accepted 3 December 2009
- continuous subcutaneous insulin infusion;
- glycaemic control;
- Type 1 diabetes
Diabet. Med. 27, 339–347 (2010)
Aims To identify variables that predict glycaemic control in Type 1 diabetic patients switched to a continuous subcutaneous insulin infusion (CSII) regimen, in order to improve patient selection for this treatment.
Methods The notes of 421 Type 1 diabetic patients aged 2.6–39.8 years (median 19.4) who initiated CSII treatment in 1998–2007 and used it for ≥ 1 year were reviewed. Details about their background and disease-related and treatment-related variables were recorded. At pump initiation, the mean age was 15.9 ± 7.2 years, mean diabetes duration 6.4 ± 5.8 years. Mean time of CSII use was 4.1 ± 2.1 years. Good glycaemic control was defined by glycated haemoglobin (HbA1c) stratified by age (American Diabetes Association target levels). Improvement in glycaemic control was defined as a reduction of ≥ 0.5% in HbA1c from baseline. The change in the rate of severe hypoglycaemic or diabetic ketoacidosis events was also determined.
Results There was a significant sustained decrease in HbA1c with CSII for an average of 6 years, without increased rates of hypoglycaemia. Achievement of target HbA1c was significantly associated with the following parameters at pump initiation: lower HbA1c (P < 0.001), younger age (< 12 years), shorter diabetes duration (P < 0.001) and more frequent daily self blood glucose monitoring (SBGM) (P < 0.01). Improved glycaemic control was associated with longer CSII use (P = 0.032) and higher HbA1c at CSII initiation (P < 0.001).
Conclusions Switching patients to CSII resulted in sustained decrease in HbA1c and improved glycaemic control in patients with high HbA1c. Young age, frequent SBGM and lower HbA1c at pump initiation were identified as predictors of achieving glycaemic targets with CSII.